Lichen planus pigmentosus (LPP) is a rare form of lichen planus that typically affects middle-aged people with darker-pigmented skin. LPP is associated with a longer clinical course than classical lichen planus, which distinguishes it clinically. Its occurrence in children is uncommon, with few reported cases in this population in the literature. We report a rare presentation of unilateral blaschkoid LPP in a seven-year-old Saudi Arabian female patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399280 | PMC |
| http://dx.doi.org/10.7759/cureus.41354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Malignant Transformation of Oral Lichen Planus and Oral Lichenoid Lesions: A Single Centre, 10-Year Review.
Head Neck
January 2025
Oral Pathology and Oral Medicine, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.
Background: Oral lichen planus (OLP) and oral lichenoid lesions (OLL) are common chronic inflammatory diseases associated with malignant transformation. Risk factors associated with malignant transformation of OLP and OLL are not well defined.
Methods: A retrospective chart review assessed risk factors for progression of OLP and OLL to oral epithelial dysplasia (OED) or oral squamous cell carcinoma (OSCC) at a tertiary care centre in Toronto, Canada.
Colophony in Dentistry: Routes of Exposure and Reported Reactions.
Dermatitis
January 2025
Department of Dermatology, Park Nicollet Contact Dermatitis Clinic, Minneapolis, Minnesota, USA.
Colophony is a solid form of resin derived from coniferous trees that has both adhesive and water-resistant properties. For these reasons, this allergen is incorporated into many personal care products, medications, and occupational materials, and is thus commonly implicated in allergic contact dermatitis. Dedicated "dental" allergen series often include colophony, but dermatologists are likely not well-versed on its use in a dental setting.
View Article and Find Full Text PDFConcurrent management of vitiligo and acquired disorders of hyperpigmentation: a comprehensive literature review and current practice gaps.
Int J Dermatol
January 2025
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Few studies discuss the co-management of vitiligo and acquired hyperpigmentation disorders (AHD) such as melasma, erythema dyschromicum perstans, post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and lichen planus pigmentosus. This review discusses clinical studies examining co-management strategies and identifies current practice gaps. Dermatology Life Quality Index scores are higher in individuals with vitiligo or melasma.
View Article and Find Full Text PDFThe role of skin microbiota in lichen planus from a Mendelian randomization perspective.
Arch Dermatol Res
January 2025
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lichen planus is a chronic skin lesion characterized by pruritic violaceous papules, which has a high risk of morbidity. Skin microbiota plays an important role in the maintenance of cutaneous mucosal barrier and human health and immune homeostasis. Studies have shown that skin microbiota may play a role in the pathogenesis of lichen planus, but it is not yet clear.
View Article and Find Full Text PDFEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
January 2025
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
Methods: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!